<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<!DOCTYPE ichicsr SYSTEM "http://www.fda.gov/cder/aerssub/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>CEL000000000001289233</messagenumb>
    <messagesenderidentifier>CELGENE</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125102529</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">0</safetyreportversion>
    <safetyreportid lang="en">US-CELGENEUS-028-21880-13013189</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>CA</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20130125</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20130121</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20130121</receiptdate>
    <additionaldocument>2</additionaldocument>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">US-CELGENEUS-028-21880-13013189</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <primarysource>
      <reportergivename>Lucy</reportergivename>
      <reporterfamilyname>Mesode</reporterfamilyname>
      <reporterstreet>McKesson Specialty</reporterstreet>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>1</sendertype>
      <senderorganization>CELGENEUS</senderorganization>
      <senderdepartment>Global Drug Safety</senderdepartment>
      <sendertitle>Manager</sendertitle>
      <sendergivename>Vivian</sendergivename>
      <senderfamilyname>Fonseca</senderfamilyname>
      <senderstreetaddress>300 Connell Drive, Suite 6000</senderstreetaddress>
      <sendercity>Berkeley Heights</sendercity>
      <senderstate>NJ</senderstate>
      <senderpostcode>07922</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>9082190331</sendertel>
      <senderfax>9086739115</senderfax>
      <senderemailaddress>vfonseca@celgene.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>FDAPM</receiverorganization>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>A</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receivercountrycode>US</receivercountrycode>
    </receiver>
    <patient lang="en">
      <patientinitial>J-D</patientinitial>
      <patientbirthdateformat>102</patientbirthdateformat>
      <patientbirthdate>19591202</patientbirthdate>
      <patientsex>1</patientsex>
      <patientmedicalhistorytext lang="en">None provided</patientmedicalhistorytext>
      <patientdeath>
        <patientdeathdateformat>102</patientdeathdateformat>
        <patientdeathdate>20130121</patientdeathdate>
        <patientdeathcause>
          <patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
          <patientdeathreport>10063378</patientdeathreport>
        </patientdeathcause>
      </patientdeath>
      <reaction>
        <primarysourcereaction lang="en">DIED</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10011906</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10011906</reactionmeddrapt>
        <termhighlighted>3</termhighlighted>
        <reactionstartdateformat>102</reactionstartdateformat>
        <reactionstartdate>20130121</reactionstartdate>
        <reactionfirsttime>376</reactionfirsttime>
        <reactionfirsttimeunit>804</reactionfirsttimeunit>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <obtaindrugcountry>CA</obtaindrugcountry>
        <drugauthorizationnumb>21-880</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugauthorizationholder>Celgene Corporation</drugauthorizationholder>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugdosagetext lang="en">5 Milligram</drugdosagetext>
        <drugdosageform lang="en">Capsules</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10009310</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20120111</drugstartdate>
        <drugstartperiod>376</drugstartperiod>
        <drugstartperiodunit>804</drugstartperiodunit>
        <actiondrug>6</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10011906</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not Provided</drugresult>
        </drugreactionrelatedness>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical lang="en">DIED

(CANADA) Initial information was received on 21/Jan/2013 from the spouse of a 53 year-old male who received Revlimid 5mg orally from 11/Jan/2012 to an unknown date for the treatment of chronic lymphocytic leukemia (CLL).  Lot number and expiration date were not provided.  Relevant medical history and concomitant medications were not provided.  

On the morning of 21/Jan/2013, the patient died.  Cause of death was not provided.  The causal relationship of the patient's death to Revlimid was not provided.  Reporter consent to obtain follow-up information from the physician/prescriber was not authorized.  Therefore additional information cannot be requested for this case.</narrativeincludeclinical>
        <sendercomment lang="en">The temporal relationship between therapy and the patient's death [DIED] suggests that a causal relationship is possible, but the undelrying CLL could provide an alternative explanation.</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr>
